Side by side
Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Industry association · Sweden
Company · ISR
Declared costs: €600K+ a year · in the register since 2011
Medicinal products for human use · Fees and charges payable to the European Medicines Agency
Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.
Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.
Teva Pharmaceuticals Europe · filed 27 Apr 2021 · source
Teva is a strategic partner of EU healthcare systems, producing 93% of its European generic, biosimilar and innovative portfolio in plants across 15 European countries (53% of our APIs are manufactured in house, 40% of which is in Europe), and saving healthcare systems more than €7.5B across 12 countries in which we support more than 112,600 jobs.
LIF Sweden · filed 2 Nov 2023 · source
The LIF welcomes the Commission’s initiative for a modernised regulatory framework for medicines that can be more easily adapted to technological and medical developments. The LIF considers that the Commission’s objective of creating more equal access to new medicines between EU Member States is important. On the other hand, the proposal contains several elements to which Lif has strong objections.
Filed in Swedish · English published by the European Commission
LIF Sweden · filed 2 Nov 2023 · source
Replies to the EU Commission deadline 7 November 2023 Lif welcomes the Commission’s initiative for a modernised regulatory framework for medicines that can be more easily adapted to technological and medical developments. The LIF considers that the Commission’s objective of creating more equal access to new medicines between EU Member States is important.
Filed in Swedish · English published by the European Commission
Teva Pharmaceuticals Europe · filed 8 Nov 2023 · source
Teva is a strategic partner of EU healthcare systems, producing 96% of its European generic, biosimilar and innovative portfolio in plants across 15 European countries. In 2020 Teva saved the healthcare systems more than 8.4 billion EUR across 9 European countries in which we support more than 105,000 jobs.
Teva Pharmaceuticals Europe · filed 8 Nov 2023 · source
Teva is a strategic partner of EU healthcare systems, producing 96% of its European generic, biosimilar and innovative portfolio in plants across 15 European countries. In 2020 Teva saved the healthcare systems more than 8.4 billion EUR across 9 European countries in which we support more than 105,000 jobs.
LIF Sweden · filed 3 Feb 2023 · source
Lif Sweden is the trade association for the research-based pharmaceutical industry in Sweden. Lif welcomes the opportunity to comment on the EU Commissions EMA fees proposal. The up-coming revision of the EU regulatory system is an opportunity to make the system faster, more efficient and flexible and thereby strengthen EU global competitiveness.
Teva Pharmaceuticals Europe · filed 7 Feb 2023 · source
At Teva pharmaceuticals, our mission is to improve the lives of patients across the globe. In Europe, Teva is a strategic partner of healthcare systems, producing 96% of its European generic, biosimilar and innovative portfolio in plants across 15 European countries (53% of our APIs are manufactured in-house, 40% of which are in Europe), and 2020 saving healthcare systems more than 8.4.
2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.